[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 69 of about 69
1. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising from recurrent anal fistula.
  • Here, we report on a patient with squamous cell carcinoma (SCC) arising from recurrent anal fistula.
  • The patient was a 57-year-old woman who had 32-year history of having a recurrent perianal abscesses that ruptured spontaneously.
  • Six months before her admission to our hospital, anal pain developed.
  • Physical examination revealed three external fistulous openings at the two o'clock position, 2 cm from the anal verge.
  • Microscopic examination showed SCC arising from the anal fistula, which was accompanied by vessel invasion.
  • Histopathological examination revealed transitional cell carcinoma of the urinary bladder.
  • Our patient had MSI and one of the smallest reported SCCs arising from recurrent anal fistulae.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Rectal Fistula / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878704.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Troicki F, Pappas A, Noone R, Denittis A: Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. J Med Case Rep; 2010;4:67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report.
  • INTRODUCTION: High-grade anal intraepithelial neoplasia, also referred to as anal squamous carcinoma in-situ, or Bowen's disease of the anus, make up less than 1% of all digestive system cancers in the United States.
  • The treatment of choice is surgical resection with anal mapping.
  • This can compromise the anal sphincter leading to leakage.
  • In this case report, we discuss the efficacy of radiation therapy as a modality to treat post-excisional recurrent Bowen's disease, which may prevent sphincter compromise, leading to improved quality of life.
  • CASE PRESENTATION: An 84-year-old Caucasian woman presented with post-excisional persistent/recurrent squamous cell carcinoma in-situ.
  • The initial lesion measured 3 cm in diameter on the right lateral side of the anal margin.
  • A standard surgery consisting of wide local excision with anal mapping was performed.
  • Our patient recurred with a 1.2 x 0.8 cm lesion on the left anal verge extending to the anal canal.
  • A biopsy along with mapping was done, and 2 of the 17 mapping specimens were positive for carcinoma in-situ, one in the anal canal.
  • Due to the location of the positive anal mapping, and in order to prevent sphincter compromise on re-excision, our patient was offered definitive radiation therapy.
  • Two years after radiation therapy, our patient showed no signs of recurrent disease and had good sphincter control.
  • CONCLUSION: Although the main treatment modality for treating persistent/recurrent Bowen's disease is surgery, an alternative approach using external beam radiation for CIS may be enough to provide a cure for some patients with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S25-33 [15753009.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Br J Surg. 1997 May;84(5):675-8 [9171763.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Urol Clin North Am. 1992 Feb;19(1):83-91 [1310549.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 20181236.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2841077
  •  go-up   go-down


3. Puglisi M, Varaldo E, Assalino M, Ansaldo G, Torre G, Borgonovo G: Anal metastasis from recurrent breast lobular carcinoma: a case report. World J Gastroenterol; 2009 Mar 21;15(11):1388-90
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal metastasis from recurrent breast lobular carcinoma: a case report.
  • We report a case of isolated gastrointestinal metastasis from breast lobular carcinoma, which mimicked primary anal cancer.
  • Four years later, she presented with an anal polypoid lesion.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Surgery. 1993 Oct;114(4):637-41; discussion 641-2 [8211676.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):338-47 [15737028.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1745-50 [16721370.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):453-5 [11289296.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):71-3 [12488295.001]
  • [Cites] Ann Chir. 1983 May;37(4):281-4 [6625502.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):307-10 [3954484.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Tech Coloproctol. 2005 Dec;9(3):237-8 [16328121.001]
  • (PMID = 19294770.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2658842
  •  go-up   go-down


Advertisement
4. Nahas SC, Nahas CS, Silva Filho EV, Levi JE, Atui FC, Marques CF: Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report. Sao Paulo Med J; 2007 Sep 6;125(5):292-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report.
  • CONTEXT: Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients.
  • Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
  • CASE REPORT: A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts.
  • He presented some condylomatous spreading lesions occupying part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm.
  • Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion.
  • The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions.
  • However no invasive squamous cell carcinoma recurrence has been detected so far.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. DNA, Viral / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis


5. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • [Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • Most patients had squamous cell carcinoma (n=30).
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


6. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P, Swoboda J, Pfister H, Wieland U, German Competence Network HIV/AIDS: Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol; 2008 Aug;128(8):2078-83
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men.
  • Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men having sex with men (MSM).
  • Standardized follow-up examinations included high-resolution anoscopy, anal cytology/histology, HPV typing, and DNA load determination for HPV types 16, 18, 31, and 33.
  • Five patients (26%) had recurrent high-grade AIN after a mean time of 24.6 months.
  • During follow-up, 58% of all patients (11/19) developed new anal cytological abnormalities in previously normal, untreated anal regions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma in Situ / drug therapy. DNA, Viral / drug effects. HIV Infections / complications. Papillomaviridae / genetics

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273049.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / DNA, Viral; 99011-02-6 / imiquimod
  • [Investigator] Adam A; Schewe K; Weitner L; Aratesh K; Arendt G; Bartz C; Behrens G; Beichert M; Bieniek B; Cordes C; Bochow M; Brockmeyer N; Buchholz B; Bogner JR; Buhk T; Clad A; Dannecker M; Dupke S; von Einsiedel R; Esser S; Faetkenheuer G; Fischer K; Freiwald M; Friebe-Hoffmann U; Fenske S; Funk M; Ganschow R; Gingelmaier A; Glaunsinger T; Goebel FD; Gölz J; Grosch-Wörner I; Haberl A; Hamouda O; Harrer T; Hartmann M; Hartl H; Hölscher M; Hower M; Husstedt IW; Jansen K; Jäger H; Jessen H; Jessen A; Karwat M; Klausen G; Kirchhoff F; Knechten H; Köppe S; Kreuter A; Kuhlmann B; Langer P; Lauenroth-Mai; Lehmacher W; Lehmann M; Levin C; Lübke M; Maschke M; Marcus U; Mauss S; Meyerhans A; Meyer-Olson D; ter Meulen V; Michalik C; Moll A; Mosthaf FA; Mutz A; Neuen-Jacob E; Niehues T; Oette M; Paulus U; Plettenberg A; Potthoff A; Racz P; Racz K; Rasokat H; Rausch M; Reichelt D; Reitter A; Rieke A; Rockstroh J; Salzberger B; Schafberger A; Schauer J; Schlote F; Schmidt B; Schranz D; Scholten S; Schuler C; Schwab M; Schmidt W; Schmidt R; Schwarze S; Siffert W; Skaletz-Rorowski A; Sonnenberg-Schwan U; Sopper S; Spengler U; Staszewski S; Steffan E; Stellbrink HJ; Stoll M; Goecke T; Taubert S; Telschik A; Ulmer A; Ullrich R; Uberla K; Usadel S; Vogel M; Wagner R; Walter H; Warnatz K; Wasem J; Wiesel W; Von Weizsäcker K; Wieland U; Wintergerst U; Wolf E; Wolf H; Wünsche T; Wyen Ch; Zeitz M; Zylka-Menhorn V
  •  go-up   go-down


7. Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IeM: Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol; 2010;2010:285191
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.
  • Our previous reports demonstrated that NAC1, a BTB/POZ domain-containing nuclear protein, upregulates in recurrent ovarian serous carcinoma and participates in developing drug resistance in cancer cells.
  • Immunohistochemistry showed that NAC1 and FASN immunointensities in ovarian serous carcinoma tissues had a highly significant correlation (P < .0001).
  • Moreover, we found that recurrent serous carcinomas exhibited higher FASN immunointensities than their matched primary tumors (P < .001).
  • The dependence of drug resistant tumor cells on FASN suggests a potential application of FASN-based therapeutics for recurrent ovarian cancer patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Cell. 2008 Mar 21;132(6):1049-61 [18358816.001]
  • [Cites] Urology. 1995 Jan;45(1):81-6 [7817483.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83 [8022791.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):474-82 [8630954.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1189-93 [8640795.001]
  • [Cites] Hum Pathol. 1996 Sep;27(9):917-21 [8816886.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2458-64 [18413838.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3149-55 [18483383.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2616-8 [18509172.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4088-97 [18682509.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5332-40 [18765524.001]
  • [Cites] Biochem J. 2009 Jan 1;417(1):313-22 [18774944.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):478-86 [18823650.001]
  • [Cites] Lab Invest. 2008 Dec;88(12):1340-8 [18838960.001]
  • [Cites] Mol Cancer Ther. 2008 Dec;7(12):3816-24 [19074856.001]
  • [Cites] Neurochem Int. 2009 Mar-Apr;54(3-4):245-52 [19121354.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):214-24 [19139131.001]
  • [Cites] Oncogene. 2009 May 7;28(18):1941-8 [19305429.001]
  • [Cites] J Biol Chem. 2009 Jun 12;284(24):16071-81 [19366700.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jul 31;385(3):454-9 [19467222.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):201-8 [9006336.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):686-92 [9191002.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4285-300 [9331090.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4611-5 [9788612.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2115-20 [9815604.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2114-23 [11448931.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Mol Cancer Res. 2003 Aug;1(10):707-15 [12939396.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1994-2000 [15753399.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3574-82 [15806173.001]
  • [Cites] J Neurochem. 2005 Aug;94(3):786-93 [16033423.001]
  • [Cites] Trends Pharmacol Sci. 2005 Nov;26(11):541-4 [16169094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44 [17130457.001]
  • [Cites] J Neurochem. 2007 May;101(3):611-8 [17254023.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):1030-6 [17391728.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2964-71 [17409402.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1263-8 [17786030.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):973-80 [17786362.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8058-64 [17804717.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6842-9 [17982121.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11933-41 [18089824.001]
  • [Cites] Bioinformatics. 2008 Feb 15;24(4):458-61 [18203771.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1003-11 [18281474.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):263-70 [18281512.001]
  • [Cites] J Pathol. 1995 Aug;176(4):343-52 [7562249.001]
  • (PMID = 20508725.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2873657
  •  go-up   go-down


8. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


9. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • In all, 7 patients with recurrent disease underwent surgery and subsequent histological correlation was performed.
  • RESULTS: Primary and recurrent tumours were of high signal intensity relative to skeletal muscle on T2-weighted images (T2WI), and of low to intermediate signal intensity on T1-weighted images (T1WI).
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • Recurrent tumours were more locally advanced than primary tumours and extended into adjacent organs and the pelvic skeleton.
  • Recurrent lymph node disease involved perirectal, presacral and internal iliac nodes more commonly than did primary lymph node disease.
  • MR has a role in the preoperative evaluation and surgical planning of cases of recurrent disease following radiotherapy.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA: Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum; 2006 Oct;49(10):1527-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anal endosonography may improve detection of recurrent anal cancer.
  • PURPOSE: In our center since 2001, follow-up examination has included three-dimensional endosonography in all patients with suspicion of local recurrence of anal cancer.
  • METHODS: This prospective study included 38 consecutive patients who have had anal carcinoma and were investigated using three-dimensional endosonography in combination with anoscopy and digital rectal examination at Rigshospitalet from July 2001 to January 2005 under suspicion of local recurrence.
  • CONCLUSIONS: This study indicates that three-dimensional endosonography surpasses two-dimensional endosonography in the evaluation of patients with suspicion of local recurrence of anal cancer especially in combination with anoscopy and digital rectal examination.
  • [MeSH-major] Anal Canal / ultrasonography. Anus Neoplasms / ultrasonography. Endosonography / methods. Imaging, Three-Dimensional. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988854.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg; 2005 Nov;29(11):1452-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
  • The primary treatment for anal cancer is chemoradiation (CRT).
  • A major problem of surgery in the anal area is poor healing of the perineal wound.
  • Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed.
  • In the present study salvage APR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1525-9 [9769399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Surg Gynecol Obstet. 1970 Nov;131(5):953-7 [5471546.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):525-9 [3942984.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):997-1005 [11240240.001]
  • [Cites] Br J Surg. 2003 May;90(5):575-80 [12734865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1007-13 [11240241.001]
  • [Cites] Plast Reconstr Surg. 1988 Jan;81(1):62-73 [2962215.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):105-10 [7834434.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):405-9 [10430247.001]
  • [Cites] Clin Plast Surg. 1990 Oct;17(4):705-12 [2249391.001]
  • [Cites] AJR Am J Roentgenol. 1979 Nov;133(5):790-5 [115262.001]
  • [Cites] Dis Colon Rectum. 1989 Sep;32(9):773-7 [2503342.001]
  • [Cites] Proc R Soc Med. 1941 Jan;34(3):139-60 [19992316.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1090-3; discussion 1094-5 [10982516.001]
  • [Cites] Surg Gynecol Obstet. 1985 Dec;161(6):509-17 [3934775.001]
  • [Cites] Br J Plast Surg. 1984 Jul;37(3):330-50 [6234962.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • (PMID = 16222445.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Martin FT, Kavanagh D, Waldron R: Squamous cell carcinoma of the anal canal. Surgeon; 2009 Aug;7(4):232-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal.
  • Squamous cell carcinoma ofthe anal canal represents 1.5% of all malignancies affectingthe gastrointestinal tract.
  • Work by Nigro et al. has revolutionised how we currently manage carcinoma of the anal canal, demonstrating combined modality chemoradiotherapy as an appropriate alternative to surgical resection with the benefit of preserving sphincter function.
  • Surgery is then reserved for recurrent disease with salvage abdominoperineal resection.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736891.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 57
  •  go-up   go-down


14. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice.
  • RESULTS: Eleven patients underwent radical salvage surgery for persistent disease and 20 patients for recurrent disease.
  • Twelve patients developed recurrent disease after radical salvage surgery.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Subramonia Iyer S, Akl A: A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004. J Clin Oncol; 2009 May 20;27(15_suppl):e15131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004.
  • : e15131 Background: This paper describes the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry.
  • The Hurley cancer registry was searched using diagnosis codes for anal cancer.
  • RESULTS: Over a period of 18 years (1987 - 2004), there were 36 patients enrolled in the registry, with a diagnosis of anal cancer.
  • Five patients (14%) developed recurrent disease during follow up, after a median of 1.8 years (range: 0.67- 4.2 years).
  • Three of the five (60%) recurrent cancers were associated with HIV infection.
  • Squamous cell carcinoma is the commonest (75%) anal cancer.
  • 2. The risk of recurrence of anal cancer was 14% over 6-years, and 80% of recurrence was localised to the anal canal.
  • This was 78.9% for the subgroup of patients without recurrence, and 86.1% for the subgroup with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sarzo G, Del Mistro A, Finco C, Frayle-Salamanca H, Marino F, Franzetti M, Ferrara R, Mistrangelo M, Savastano S, Vecchiato M, Merigliano S: Extensive anal condylomatosis: prognosis in relation to viral and host factors. Colorectal Dis; 2010 Jul;12(7 Online):e128-34
HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive anal condylomatosis: prognosis in relation to viral and host factors.
  • OBJECTIVE: To evaluate the clinical course of extensive anal condylomatosis in relation to treatment modalities, patient comorbidity and immune function, and associated papillomavirus (HPV) sequences.
  • RESULTS: Sixteen patients [14 males, median age 41.8 years (range 19-66)] affected by extensive anal condylomatosis [10 Buschke-Lowenstein Tumors (BLT) and 6 condylomatosis] treated in three different Italian institutions were included.
  • There was associated preoperative anal intraepithelial neoplasia grade 3 (AIN3) in one and invasive carcinoma in three patients.
  • Viral variant L83V was present in 3/4 HPV 16 positive recurrent cases.
  • Typing of HPV sequences in the management of patients affected by extensive anal condylomatosis may be useful.

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Colorectal Dis. 2010 Oct;12(10):1072. Mistro, A [corrected to Del Mistro, A]
  • (PMID = 19508521.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


17. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
  • Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.
  • Few treatment options exist for recurrent metastatic vulvar carcinoma.
  • The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Haboubi NY, Edilbe MW, Hill J: Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline. Colorectal Dis; 2007 Mar;9(3):238-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline.
  • The currently accepted first line treatment for epidermoid anal cancer is chemoradiotherapy (CRT).
  • Residual or recurrent disease following initial CRT, is best treated by salvage anorectal excision.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298622.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Zampino MG, Magni E, Sonzogni A, Renne G: K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol; 2009 Dec;65(1):197-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?
  • PURPOSE: Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1-5% of all intestinal tumours.
  • The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated.
  • This observation previously reported in other tumours has supported the effective use of EGFR-inhibitors in recurrent or metastatic disease.
  • [MeSH-major] Anus Neoplasms / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727729.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


20. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • Resection is now reserved for persistent or recurrent disease.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie; 2006 Feb;29(1-2):30-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature.
  • BACKGROUND: We report on a patient with squamous cell anal carcinoma and liver metastases, who underwent multimodal treatment for cure, consisting of repeated partial hepatectomy in combination with chemoradiotherapy.
  • PATIENTS AND METHODS: A 54-year-old woman presented with squamous cell anal carcinoma and liver metastases.
  • 2 and 5 years after presentation, the patient underwent repeated partial hepatectomies for recurrent liver disease.
  • RESULTS: Repeated partial hepatectomy led to prolonged survival in a patient with squamous cell anal carcinoma metastatic to the liver.
  • CONCLUSIONS: This is the first report of aggressive partial hepatectomy for recurrent liver metastases resulting from anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • (PMID = 16514253.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


23. Tilney HS, Heriot AG, Trickett JP, Massouh H, Edwards DP, Mellor SG, Gudgeon AM: The use of intra-operative endo-anal ultrasound in perianal disease. Colorectal Dis; 2006 May;8(4):338-41
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of intra-operative endo-anal ultrasound in perianal disease.
  • Pathologies encountered were fistula-in-ano (42%), fissure-in-ano (26%), complicated perianal sepsis (16%) and carcinoma (5%).
  • While not essential, it is a useful adjunct especially in recurrent perianal sepsis, undiagnosed anorectal pain and anal fissure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630240.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, Easson A, Smith AJ, Swallow CJ: Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol; 2007 Oct;14(10):2780-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
  • BACKGROUND: For patients with anal canal cancer who fail combined modality treatment (CMT), salvage surgery (SS) offers the potential for long term survival.
  • METHODS: We identified 60 patients with persistent or recurrent anal cancer who had undergone SS; 20 were excluded.
  • CONCLUSION: SS for anal canal cancer was associated with significant morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Cancer Care Facilities. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ontario. Registries. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638059.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Goldstone SE, Hundert JS, Huyett JW: Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis Colon Rectum; 2007 May;50(5):565-75
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males.
  • PURPOSE: The incidence of anal squamous carcinoma in males who have sex with males is rising.
  • METHODS: We performed a retrospective review of medical records on HIV-negative males who have sex with males who had infrared coagulation ablation of anal high-grade squamous intraepithelial lesions.
  • Recurrent high-grade squamous intraepithelial lesions were retreated.
  • HIV-positive patients were twice as likely to have lesions persist and 1.7 times more likely to develop a recurrent high-grade squamous intraepithelial lesion.
  • No patient developed squamous-cell carcinoma, anal stenosis, or had a serious complication.
  • CONCLUSIONS: Infrared coagulation is a safe and effective office-based procedure for treating anal high-grade squamous intraepithelial lesions.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. HIV Seronegativity. Homosexuality, Male. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380365.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL: HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum; 2009 May;52(5):891-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV and anal cancer outcomes: a single institution's experience.
  • PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal.
  • METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006.
  • Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009).
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality. HIV Infections / mortality


27. Goldstone SE, Kawalek AZ, Huyett JW: Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum; 2005 May;48(5):1042-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions.
  • PURPOSE: The incidence of invasive anal squamous carcinoma in men who have sex with men is rising, particularly in those with human immunodeficiency virus.
  • As in the cervix the high-grade squamous intraepithelial lesion is thought to be an invasive squamous cell carcinoma precursor.
  • Better office-based techniques to treat anal high-grade squamous intraepithelial lesions are needed.
  • Follow-up consisted of anal cytology with high-resolution anoscopy and biopsy of suspicious areas every three to six months.
  • New or recurrent high-grade dysplasia was retreated.
  • No patient developed squamous-cell carcinoma, had a serious adverse event, or developed anal stenosis.
  • CONCLUSIONS: The infrared coagulator is a safe, office-based modality for treating anal high-grade squamous intraepithelial lesion in human immunodeficiency virus-positive men who have sex with men.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. HIV Seropositivity. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery


28. Taniguchi M, Ookubo K, Ootsuka M, Akitake H, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Tsujie M, Konishi M, Ebisui C, Fujimoto T: [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2315-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
  • We have experienced a case of successful control of recurrent duodenal carcinoma receiving paclitaxel chemotherapy.
  • A 61-year-old woman with epigastralgia was diagnosed with pyloric gastric carcinoma upon upper gastrointestinal endoscopy and biopsy.
  • So, we additionally resected the anal edge.
  • And 13a, 13b, 12a, p lymph nodes were dissected for duodenal carcinoma.
  • Recurrence of the duodenal carcinoma was diagnosed in February 2007, and S-1 administration was begun.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037407.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.3.1.21 / Carnitine O-Palmitoyltransferase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Sunesen KG, Buntzen S, Tei T, Lindegaard JC, Nørgaard M, Laurberg S: Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol; 2009 Jan;16(1):68-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap.
  • Salvage surgery of recurrent or persistent anal cancer following radiotherapy is often followed by perineal wound complications.
  • We examined survival and perineal wound complications in anal cancer salvage surgery during a 10-year period with primary perineal reconstruction predominantly performed using vertical rectus abdominis myocutaneous (VRAM) flap.
  • Between 1997 and 2006, 49 patients underwent anal cancer salvage surgery.
  • We conclude that anal cancer salvage surgery can yield long-time survival but obtaining free margins is critical.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / therapy. Salvage Therapy. Survival Rate. Time Factors. Treatment Outcome


30. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • The complete response rate was 67% (SqCC, 23/33; adenocarcinoma, 5/9); of 12 patients who failed treatment, primary tumor was the recurrent site in seven (median failure time, 5 months): six patients underwent salvage abdominoperineal resection.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • Tumor response (median survival since first TACP) was as follows: colorectal: 2 PR, 7 SD, 2 PD (11.5 months), ovarian: 1 SD, 2 PD (8.5 mon), cervical: 1 PR, 1 SD (6 mon), breast: 2 SD (6 mon), gastric: 1 PD (11 mon), adrenal gland: 1 PD (12 mon), anal: 1 PD (10 mon), prostate: 1 PD (20 mon), Gartner's duct: 1 PR (20 mon), renal cell carcinoma: 1 SD (10 mon).
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


32. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • Recurrent high-grade squamous intraepithelial lesions occurred in 114 patients (57 percent) at an average 19 (range, 3-92) months; 26 of these required surgery.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Sandiford N, Prussia PR, Chiappa A, Zbar AP: Synchronous mucinous adenocarcinoma of the rectosigmoid seeding onto a pre-existing anal fistula. Int Semin Surg Oncol; 2006;3:25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous mucinous adenocarcinoma of the rectosigmoid seeding onto a pre-existing anal fistula.
  • Carcinoma within a long-standing fistula-in-ano is rare and may be defined by specific neoplastic involvement of the fistulous track in the absence of rectal mucosal carcinoma.
  • The presence of a carcinoma of mucinous histology occurring synchronously in the perianal region and the colon is exceptionally rare.
  • Subsequent clinical follow-up and CT examination of the patient has not revealed recurrent disease at 14 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Mar;39(3):1295-9 [199346.001]
  • [Cites] J R Soc Med. 1992 Jun;85(6):361 [1625275.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):544-5; author reply 545 [14994107.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):835-6 [12794588.001]
  • [Cites] Chirurg. 2001 May;72(5):573-7 [11383070.001]
  • [Cites] South Med J. 1979 Jun;72(6):764-6 [221988.001]
  • [Cites] Postgrad Med J. 1987 Jun;63(740):503-4 [2829151.001]
  • [Cites] Am J Clin Pathol. 1988 Jun;89(6):809-12 [2835897.001]
  • [Cites] Am J Gastroenterol. 1988 Apr;83(4):460-2 [3348199.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):68-70 [3366030.001]
  • [Cites] J R Soc Med. 1988 Apr;81(4):217-9 [3373467.001]
  • [Cites] Postgrad Med J. 1987 Mar;63(737):213-4 [3671263.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Am J Proctol. 1970 Apr;21(2):103-12 [4330480.001]
  • [Cites] Rev Esp Enferm Dig. 1995 Apr;87(4):342-3 [7794647.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1050-2 [7648150.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] JAMA. 1970 Sep 21;213(12):2083 [5468765.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):562-6 [6271516.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • (PMID = 16961916.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1592294
  •  go-up   go-down


34. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • The aim of this study was to examine our experience with abdominoperineal resection (APR) in cases of persistent or recurrent SCCA with an emphasis on survival and morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):159-64 [3969957.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):105-10 [7834434.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • (PMID = 17846856.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY: Mucinous carcinoma in Crohn's disease originating in a fistulous tract. World J Gastrointest Oncol; 2010 Jul 15;2(7):307-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma in Crohn's disease originating in a fistulous tract.
  • An 18-year-old male with extensive small and large bowel involvement with Crohn's disease developed recurrent peri-rectal fistulous disease that persisted for more than a decade despite pharmacological and surgical therapy as well as later therapy with biological agents.
  • Eventually, an extensive and difficult-to-detect mucinous carcinoma developed in the fistulous tract.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160662.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999135
  • [Keywords] NOTNLM ; Adalimumab / Anal fistula / Anorectal adenocarcinoma / Crohn’s disease / Fistula carcinoma / Infliximab / Tumor necrosis factor antibodies
  •  go-up   go-down


36. Wang H, Fu CG, Zheng JM, Gong HF, Tao LY, Yu ED, Zhang W, Liu LJ, Hao LQ, Meng RG: [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):569-72
MedlinePlus Health Information. consumer health - Biopsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma].
  • OBJECTIVE: To analyze the impact of meticulousness of pathologists on the lymph node harvest after radical resection of invasive rectal carcinoma.
  • Excluded criteria were recurrent colorectal tumor, Tis tumor, R(1) or R(2) resection, tumor resection transanally or endoscopically, the cases enrolled in other prospective research, synchronous diseases affecting the surgical procedure for the rectal cancer (familial adenomatous polyposis, synchronous colorectal carcinoma) and rectal cancer receiving neoadjuvant chemoradiation.
  • There were no significant differences in gender (46/76 vs 86/156, P=0.436), age (58.1+/-1.3 vs 59.2+/-1.1, P=0.527), distance from tumor to anal verge (7.4+/-0.4 vs 7.1+/-0.3, P=0.761), proportion of sphincter-sparing surgery (67/76 vs 140/156, P=0.715), ratio of well and moderate differentiated tumors (68/76 vs 125/156, P=0.074) and overall TNM stage (P=0.167) between the two groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921565.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


37. Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL Jr, Zhang HZ, Kamat A, Katz RL: Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol; 2010 Oct 25;118(5):259-68
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study.
  • BACKGROUND: Because urothelial carcinoma (UC) is associated with a significantly high risk of disease recurrence and progression, patients with UC require long-term surveillance.
  • RESULTS: A total of 1006 consecutive urinary specimens from 600 patients (448 men and 152 women) who were monitored for recurrent UC (915 specimens) or evaluated for urinary symptoms (91 specimens) were identified.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • [Cites] J Urol. 2000 Nov;164(5):1768-75 [11025767.001]
  • [Cites] Diagn Cytopathol. 2009 Oct;37(10):773-9 [19626630.001]
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):79-86 [11447756.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Dec;23(6):381-7 [11777271.001]
  • [Cites] J Urol. 2002 May;167(5):2001-6 [11956427.001]
  • [Cites] J Urol. 2002 Nov;168(5):1950-4 [12394683.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):374-9 [12478686.001]
  • [Cites] Eur Urol. 2002 Dec;42(6):547-52 [12477649.001]
  • [Cites] J Urol. 2003 Jun;169(6):1975-82 [12771702.001]
  • [Cites] J Urol. 2003 Jun;169(6):2101-5 [12771727.001]
  • [Cites] Urology. 1998 Sep;52(3):398-402 [9730450.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Feb;21(1):29-34 [10068772.001]
  • [Cites] J Urol. 1999 Jul;162(1):53-7 [10379739.001]
  • [Cites] J Urol. 2005 Feb;173(2):401-4 [15643180.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):945-6 [15848583.001]
  • [Cites] BJU Int. 2005 Jun;95(9):1219-25 [15892805.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1280-5 [16287445.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):854-61 [16416734.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):299-305 [16418465.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Dec;27(6):317-22 [16450788.001]
  • [Cites] J Urol. 2006 Jul;176(1):44-7 [16753364.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):338-43 [16818188.001]
  • [Cites] J Appl Genet. 2006;47(3):273-5 [16877809.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Jun;25(2):145-60 [16918124.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1660-5 [16646074.001]
  • [Cites] Cytogenet Genome Res. 2006;114(3-4):279-83 [16954667.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5528-35 [17158538.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):295-301 [17210520.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Mar;173(2):131-5 [17321328.001]
  • [Cites] Eur Urol. 2007 May;51(5):1275-80; discussion 1280 [17084511.001]
  • [Cites] Pathol Oncol Res. 2007;13(3):187-94 [17922047.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Adv Anat Pathol. 2008 Sep;15(5):279-86 [18724101.001]
  • [Cites] Urol Oncol. 2008 Nov-Dec;26(6):646-51 [18367109.001]
  • [Cites] Int J Cancer. 2009 Jun 15;124(12):2899-904 [19230026.001]
  • [Cites] Cancer. 2009 Jun 25;117(3):167-73 [19365828.001]
  • [Cites] J Mol Diagn. 2000 Aug;2(3):116-23 [11229514.001]
  • (PMID = 20665656.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA016672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS219560; NLM/ PMC2993817
  •  go-up   go-down


38. Brunner A, Schönhuber G, Waldner M, Schaefer G, Mikuz G, Verdorfer I: Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system. Anal Quant Cytol Histol; 2008 Oct;30(5):297-305
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system.
  • OBJECTIVE: To evaluate differences in chromosomal aberrations in recurrent urothelial cancer (UC) of the bladder between the World Health Organization (WHO) 1973 and 2004 classification a retrospective study was performed.
  • STUDY DESIGN: Primary and recurrent UCs of the bladder of 22 patients diagnosed at the Institute of Pathology, Medical University of Innsbruck were analyzed by comparative genomic hybridization, fluorescence in situ hybridization and immunohistochemistry (Ki-67, p53).

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980162.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Lillo FB: Human papillomavirus infection and its role in the genesis of dysplastic and neoplastic lesions of the squamous epithelia. New Microbiol; 2005 Apr;28(2):111-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extensive laboratory and epidemiological evidence demonstrate that human papillomavirus (HPV) is the major cause of squamous cervical carcinoma (SCC), its precursor lesions (cervical intraepithelial neoplasia - CIN) and several other benign and malign clinical manifestations including genital warts, condylomata acuminata, Bowenoid papulosis, vaginal, vulvar and anal intraepithelial neoplasia (VIN and AIN) and carcinoma, penile carcinoma and other squamous neoplasias of the head and neck districts.
  • In addition, mother-to-child transmission is probably responsible for recurrent laryngeal and pulmonary papillomatosis in infants.
  • The relevance and high level of scientific interest surrounding HPVs are related to the oncogenic potential of some viral types belonging to this family and the possibility to influence the incidence of various tumour forms likecervical carcinoma, improving the efficacy of specific screening programs or defining preventive strategies like vaccination.
  • [MeSH-major] Carcinoma, Squamous Cell. Cervical Intraepithelial Neoplasia. Papillomaviridae / pathogenicity. Papillomavirus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035255.001).
  • [ISSN] 1121-7138
  • [Journal-full-title] The new microbiologica
  • [ISO-abbreviation] New Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 40
  •  go-up   go-down


40. Ramamoorthy S, Luo L, Luo E, Carethers JM: Tobacco smoking and risk of recurrence for squamous cell cancer of the anus. Cancer Detect Prev; 2008;32(2):116-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Squamous cell cancer of the anus is associated with multiple risk factors, including infection with human papillomavirus, immunosuppression, chronic inflammation, and tobacco smoking, although there is little data on these factors for the prediction of recurrent disease.
  • Here, we evaluated the risk of recurrence and mortality of anal carcinoma in association with tobacco smoking.
  • METHODS: We conducted a retrospective review of cases of anal carcinoma from two local hospitals.
  • Current smokers had higher carcinoma recurrence rates (11/34, 32%) than non-smokers (6/30, 20%).
  • CONCLUSION: Tobacco smoking appears to be associated with anal carcinoma disease recurrence, and is related to increased mortality.
  • This data suggests that patients should be cautioned about tobacco smoking once a diagnosis of anal carcinoma is made in attempt to improve their long-term outcome.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2337-45 [10590376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Anesth Analg. 1986 Nov;65(11):1186-8 [3767017.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Prev Med. 1995 Jul-Aug;11(4):245-50 [7495601.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):853-8 [16815535.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):808-12 [11017836.001]
  • (PMID = 18639388.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NIDDK NIH HHS / DK / DK067287-01A2; United States / NIDDK NIH HHS / DK / R24 DK080506-01; United States / NIDDK NIH HHS / DK / R01 DK067287-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS209533; NLM/ PMC3427794
  •  go-up   go-down


41. Sauer CJ, Klaase JM, Gerritsen JJ, Mastboom WJ: [A malignant tumour in the breast is not always primary breast cancer]. Ned Tijdschr Geneeskd; 2005 Apr 2;149(14):729-34
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a 75-year-old woman with a swelling in her left breast, a 39-year-old woman with an anal fissure due to diarrhoea and a 65-year-old woman with chest pain, a mammary tumour was diagnosed that did not originate in mammary tissue.
  • These were a recurrent melanoma, a carcinoma of the thyroid and a B-cell lymphoma, respectively.
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / secondary. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Melanoma / diagnosis. Melanoma / secondary. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1426; author reply 1426 [15997699.001]
  • (PMID = 15835620.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


42. Brown HM, Wilkinson EJ: Cytology of secondary vulvar Paget's disease of urothelial origin: a case report. Acta Cytol; 2005 Jan-Feb;49(1):71-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most commonly, this is due to an anal or rectal adenocarcinoma or a urothelial carcinoma.
  • CASE: An 81-year-old woman with a past history of urothelial carcinoma in situ of the bladder presented severalyears subsequent to treatment for bladder cancer with extensive vulvar and vaginal disease, clinically interpreted as primary vulvar Paget's disease involving the vagina.
  • Subsequent investigation of her bladder showed recurrent urothelial carcinoma in situ with extensive spread to the vagina and vulva, simulating primary cutaneous vulvar Paget's disease.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma / pathology. Female. Humans. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717759.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • RESULTS: The first patient had a good symptomatic response to the chemoradiation but unfortunately died of recurrent disease following surgery.
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA, European Association of Urology (EAU) Guidelines Group on Penile Cancer: EAU penile cancer guidelines 2009. Eur Urol; 2010 Jun;57(6):1002-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Squamous cell carcinoma (SCC) of the penis is a relatively rare but ominous disease.
  • Similarities in etiology with SCC of the head and neck, the female genitalia, and the anal canal have been found.
  • Adjuvant and neoadjuvant chemotherapy showed promising results in patients with advanced or recurrent disease.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Quality of Life / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20163910.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Switzerland
  •  go-up   go-down


45. Petrie N, Branagan G, McGuiness C, McGee S, Fuller C, Chave H: Reconstruction of the perineum following anorectal cancer excision. Int J Colorectal Dis; 2009 Jan;24(1):97-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Most patients with anal cancer receive chemoradiotherapy as first-line treatment.
  • Persistent/recurrent tumours will subsequently require an abdomino-perineal resection (APR).
  • A proportion of the 20,000 new cases of rectal carcinoma diagnosed in the UK each year receive neo-adjuvant chemoradiation and then an APR.
  • RESULTS: Between November 2000 and October 2007, 18 cases were performed (M/F = 7:11), six for anal cancer and 12 for low rectal tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / therapy. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Length of Stay. Male. Middle Aged. Neoadjuvant Therapy. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2000 Jan;105(1):171-3 [10626987.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):886-91 [11485523.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Plast Reconstr Surg. 2001 Dec;108(7):1998-2005 [11743391.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):482-6 [15736219.001]
  • [Cites] J Reconstr Microsurg. 1998 Jul;14(5):337-40 [9714040.001]
  • [Cites] Br J Surg. 2003 May;90(5):575-80 [12734865.001]
  • [Cites] Int J Colorectal Dis. 1991 Nov;6(4):193-6 [1770285.001]
  • [Cites] Wound Repair Regen. 1998 May-Jun;6(3):223-33 [9776866.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):232-8 [17143848.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1961 May;85:822-33 [13685884.001]
  • [Cites] Dis Colon Rectum. 1980 Nov-Dec;23(8):564-6 [7460694.001]
  • [Cites] Br J Plast Surg. 1996 Dec;49(8):547-54 [8976747.001]
  • [Cites] Ann R Coll Surg Engl. 1984 Sep;66(5):337-9 [6237602.001]
  • [Cites] Plast Reconstr Surg. 1988 Jan;81(1):62-73 [2962215.001]
  • [Cites] CA Cancer J Clin. 1971 Nov-Dec;21(6):361-4 [5001853.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Ann Intern Med. 1980 Sep;93(3):480-9 [6254418.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):349-54 [10201777.001]
  • [Cites] Surg Gynecol Obstet. 1981 Nov;153(5):713-6 [7292271.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Ann R Coll Surg Engl. 1995 May;77(3):229-32 [7598425.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1371-6; discussion 1376-7 [2222178.001]
  • [Cites] J Natl Cancer Inst. 1971 Oct;47(4):865-70 [5097154.001]
  • [Cites] Scand J Plast Reconstr Surg. 1975;9(1):74-6 [1162294.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1983 Jan;145(1):183-9 [6849490.001]
  • [Cites] Br J Surg. 1990 Jun;77(6):635-7 [2143427.001]
  • [Cites] Am J Surg. 1974 Feb;127(2):215-9 [4812123.001]
  • [Cites] Otolaryngology. 1978 Sep-Oct;86(5):ORL-804-11 [114952.001]
  • [Cites] Ann Plast Surg. 2004 Jan;52(1):22-6 [14676694.001]
  • [Cites] Cancer Res. 1958 Apr;18(3):305-17 [13523597.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):33-7 [10030413.001]
  • [Cites] Plast Reconstr Surg. 1988 Oct;82(4):669-77 [3420190.001]
  • [Cites] J Reconstr Microsurg. 1998 May;14(4):263-8 [9618094.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):777-83 [9240646.001]
  • [Cites] Can J Surg. 1987 May;30(3):212-4 [3580983.001]
  • [Cites] Oncologist. 2002;7(3):188-99 [12065790.001]
  • (PMID = 18688618.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ: ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol; 2010 Feb;32(1):45-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether ImmunoCyt (uCyt+) immunofluorescence and cytokeratin 20 (CK20) immunocytochemistry add additional diagnostic value in the detection of urothelial carcinoma (UC) in samples of urine liquid-based cytology (LBC).
  • RESULTS: Of 169 inpatients, 135 cases had histologic diagnoses, including 93 cases of UC with primary tumors in 68 and recurrent tumors in 25, 26 cases of other urologic malignancies and 16 cases of benign urologic lesions.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701087.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


47. Zbar AP, Shenoy RK, Chiappa A: Extended abdominoperineal resection in women: the Barbadian experience. Int Semin Surg Oncol; 2007;4:1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: We report our results of a selective approach to primary direct appositional vaginal repair versus transverse rectus abdominis flap repair (TRAM) in patients with extensive rectal/anal cancer or in cases with primary cancer of cervix, vagina or vulva involving the anal canal and anal sphincters.
  • Exenterative procedures were performed in 2 cases of primary vaginal cancer, following Wertheim hysterectomy for carcinoma of the cervix with recurrence after radiation and in 2 further cases of anal cancer with extensive pelvic recurrence after primary chemoradiation.
  • Fifteen cases are alive on follow-up with no evidence of disease; 2 patients who had recurrent carcinoma of the cervix and who underwent TRAM flap reconstruction, have recurrent disease after 5 and 6 months of follow-up, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 May;97(2):596-601 [15863165.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2229-35 [8918419.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):482-6 [15736219.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):476-81; discussion 481-2 [15714245.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct;16(5):389-94 [15657636.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):398-403 [15297179.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):610-4 [15196852.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):424-6 [14760771.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):27-33 [14699030.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):39-45 [12468340.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1144-50 [12209702.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):239-45; discussion 245-8 [11852339.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1371-6; discussion 1376-7 [2222178.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Plast Reconstr Surg. 1983 Dec;72(6):751-65 [6647599.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):890-6 [8076488.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):261-8 [16426668.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):542-8 [15882183.001]
  • (PMID = 17214895.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779795
  •  go-up   go-down


48. Felt-Bersma RJ, Cazemier M: Endosonography in anorectal disease: an overview. Scand J Gastroenterol Suppl; 2006;(243):165-74
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was first used to evaluate rectal tumours and later also to investigate benign disorders of the anal sphincters and pelvic floor.
  • AE has been used for almost every possible disorder in the anal region and has increased our insight into anal pathology.
  • Studies comparing AE with endoanal magnetic resonance imaging (MRI) have shown that both methods are equally good for demonstrating defects in the external anal sphincter; the internal anal sphincter is better visualized with AE.
  • Since recurrent cryptoglandular fistulae are complex in 50% and Crohn's fistula in 75%, it is mandatory to perform AE preoperatively in these patients to avoid missed tracts during surgery and subsequent recurrences.
  • 4. Anal carcinoma for staging.
  • In conclusion, AE images the internal and external anal sphincter with high accuracy.
  • It is easy to perform and is of particular value in the diagnosis of anal incontinence and perianal fistulae.
  • It is excellent in staging anal carcinoma and can also be used in staging rectal carcinoma, especially very low large malignant polyps.

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782637.001).
  • [ISSN] 0085-5928
  • [Journal-full-title] Scandinavian journal of gastroenterology. Supplement
  • [ISO-abbreviation] Scand. J. Gastroenterol. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 119
  •  go-up   go-down


49. Engin G: Endosonographic imaging of anorectal diseases. J Ultrasound Med; 2006 Jan;25(1):57-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Rectal carcinoma appears on endorectal sonography as a low-echogenicity lesion that abruptly interrupts the normal sequence of layers.
  • The internal anal sphincter is seen very clearly on endoanal sonography, and it is easy to appreciate atrophy and small tears of this sphincter.
  • Endoanal sonography cannot accurately show thinning of the external anal sphincter.
  • Peroxide-enhanced endoanal sonography is especially useful for patients with recurrent perianal fistulas in whom scarring should be distinguished from recurrent fistulas and detection of the internal opening.
  • CONCLUSIONS: Endosonography can accurately stage primary rectal tumors and assess the internal anal sphincter.
  • However, magnetic resonance imaging can be used a complementary modality to endosonography, especially for evaluation of external anal sphincter atrophy and deep pelvic inflammation.

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371556.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


50. Kyroudi-Voulgari A, Kouloukoussa M, Simigiatos C, Karakitsos P, Zervas A, Kittas C, Mitropoulos D: DNA ploidy and immunomarking of bladder urothelial tumors before and after intravesical bacillus Calmette-Guérin treatment. Anal Quant Cytol Histol; 2005 Feb;27(1):52-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate DNA ploidy and immunoexpression of Ki-67 and p53 as predictivefactors in cases of superficial urothelial cell carcinoma (UCC) treated with bacillus Calmette-Guérin (BCG).
  • STUDY DESIGN: Samples were obtained from 66 patients with UCC (pTa grade 3 or high grade and pT1 independent of grade or with concomitant carcinoma in situ) before and after intravesical BCG treatment.
  • RESULTS: During a mean follow-up of 63.8 months, 31 of the 66 patients developed recurrent tumors (46.9%).
  • DNA ploidy analysis showed that ploidy balance as well as degree of hyperploidy and aneuploidy were not statistically different between recurrent and nonrecurrent tumors.
  • Only proliferation index was statistically significant between recurrent and nonrecurrent tumors.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794452.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


51. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol; 2008 Mar;108(3):619-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study is to improve historical data that lack specific information about FRalpha expression in rare histological subtypes, primary disease versus metastatic foci, and recurrent disease.
  • METHODS: FRalpha expression was analyzed by immunohistochemistry on 186 primary and 27 recurrent ovarian tumors, including 24 pairs of samples obtained from the same individuals at diagnosis and at secondary debulking surgery.
  • RESULTS: FRalpha expression was apparent in 134 of 186 (72%) primary and 22 of 27 (81.5%) recurrent ovarian tumors.
  • In 21 of 24 (87.5%) matched specimens, recurrent tumors reflected the FRalpha status detected at diagnosis.
  • New findings from this study show that FRalpha expression is maintained on metastatic foci and recurrent tumors, suggesting that novel folate-targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2003 May;44(5):700-7 [12732670.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):52-7 [17582475.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1085-97 [15094208.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1219-31 [15094217.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Aug;287(2):C517-26 [15102609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6 [2062838.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5329-38 [1717147.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3396-401 [1596899.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5791-6 [8242637.001]
  • [Cites] Cancer. 1994 May 1;73(9):2432-43 [7513252.001]
  • [Cites] Int J Cancer Suppl. 1994;8:89-95 [8194901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9057-61 [7568072.001]
  • [Cites] APMIS. 1995 Sep;103(9):663-70 [7488388.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):121-6 [9583724.001]
  • [Cites] Arch Biochem Biophys. 1999 Jun 15;366(2):183-91 [10356282.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1505-12 [15634643.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):284-93 [15745749.001]
  • [Cites] Curr Pharm Biotechnol. 2005 Apr;6(2):131-50 [15853692.001]
  • [Cites] J Pharm Sci. 2005 Oct;94(10):2135-46 [16136558.001]
  • [Cites] Front Biosci. 2006;11:506-19 [16146749.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2168-72 [16172227.001]
  • [Cites] Curr Oncol Rep. 2005 Nov;7(6):451-8 [16221382.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Feb;21(1):49-60 [16480331.001]
  • [Cites] Cancer. 2006 May 1;106(9):1933-9 [16572412.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36 [16331500.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):603-9 [16704197.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1994-2004 [16767218.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1007-16 [16763819.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4254-61 [16908932.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6170-8 [17062694.001]
  • [Cites] Cancer Immun. 2007;7:6 [17346028.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):141-52 [17333345.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2557-67 [17473184.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):938-42 [17487842.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1585-92 [17551919.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Gene Ther. 2003 Jun;10(12):1018-25 [12776159.001]
  • (PMID = 18222534.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-09; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA80628; United States / NCI NIH HHS / CA / K12 CA090628-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS123756; NLM/ PMC2707764
  •  go-up   go-down


52. Beattie GC, Paul I, Calvert CH: Endoscopic transanal resection of rectal tumours using a urological resectoscope--still has a role in selected patients. Colorectal Dis; 2005 Jan;7(1):47-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A urological resectoscope can be safely and repeatedly used to resect advanced primary or locally recurrent rectal tumours by colorectal surgeons with urological expertise.
  • The median interval between resections for recurrent disease (excluding planned repeat resections) was 340 days (range 168-2337 days).
  • No patients with benign disease subsequently developed an invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Anal Canal / surgery. Proctoscopy. Rectal Neoplasms / surgery. Urologic Surgical Procedures / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606584.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Speake D, Lees N, McMahon RF, Hill J: Who should be followed up after transanal endoscopic resection of rectal tumours? Colorectal Dis; 2008 May;10(4):330-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 35 who went on to long-term follow-up post-TEM (0.6-8.1 years, median 4) four developed recurrent cancer (two local with submucosal disease and two liver metastases).
  • [MeSH-major] Adenoma. Carcinoma. Endoscopy, Gastrointestinal / methods. Microsurgery / methods. Neoplasm Recurrence, Local / prevention & control. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Case-Control Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190616.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Bosso MC, Marchesa PE, Ricchiuti A, Giacardi A, Cocchis D, Campi M, Palisi M, Salizzoni M: Proctocolectomy for ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Transplant Proc; 2009 May;41(4):1390-2
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing cholangitis is frequently associated with inflammatory bowel diseases, especially ulcerative colitis (60%-80%), which may require a proctocolectomy with ileal pouch anal anastomosis if there is no response to therapy or the appearance of colonic carcinoma.
  • Among the remaining 39 patients, 17 (43.6%) developed recurrent of sclerosing cholangitis; three required re-OLT, and among these three patients, one developed another recurrence.
  • After OLT, ulcerative colitis persisted in an active state in eight patients, requiring proctocolectomy with ileal pouch-anal anastomosis for three patients (median time after OLT was 78.6 months).
  • CONCLUSION: Proctocolectomy with ileal pouch anal anastomosis is safe in patients who underwent OLT for sclerosing cholangitis in association with ulcerative colitis.


55. Papaconstantinou HT, Bullard KM, Rothenberger DA, Madoff RD: Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Colorectal Dis; 2006 Feb;8(2):124-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Chemotherapy and radiation (C-XRT) is the first-line therapy for epidermoid carcinomas of the anal canal (ECAC).
  • Kaplan-Meier survival analysis showed an advantage for recurrent over persistent disease with 2-year and 5-year survival rates of 75%vs 34% and 28%vs 0%, respectively.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412072.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Gericke B, Raila J, Sehouli J, Haebel S, Könsgen D, Mustea A, Schweigert FJ: Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer; 2005;5:133
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Subjects were 48 women with primary invasive epithelial ovarian cancer or recurrent ovarian carcinoma.
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / biosynthesis. Carcinoma / blood. Carcinoma / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Inflammation. Middle Aged. Peroxidases / metabolism. Recurrence. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Obstet Gynecol. 2000 Feb;12(1):39-42 [10752515.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 May;4(1):7-15 [15975260.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 3:141-4 [11079131.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Anal Biochem. 2002 Feb 1;301(1):49-56 [11811966.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Muscle Nerve. 2002 Sep;26(3):417-20 [12210373.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1281-91 [12553432.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1320-4 [12553437.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1344-8 [12553442.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):191-7 [12716133.001]
  • [Cites] Hum Reprod. 2003 Jun;18(6):1259-64 [12773456.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 10;310(1):242-6 [14511677.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49707-13 [14507924.001]
  • [Cites] Nutr Cancer. 2003;46(2):148-57 [14690790.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):337-45 [14695346.001]
  • [Cites] Int J Vitam Nutr Res. 2003 Nov;73(6):423-30 [14743546.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1223-9 [15154651.001]
  • [Cites] J Obstet Gynaecol Can. 2004 Aug;26(8):717-28 [15307976.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Zentralbl Gynakol. 2004 Oct;126(5):315-22 [15478050.001]
  • [Cites] Ann Nutr Metab. 2004;48(4):241-5 [15331882.001]
  • [Cites] Curr Oncol Rep. 2004 Nov;6(6):456-62 [15485615.001]
  • [Cites] J Clin Pathol. 1991 Jul;44(7):573-5 [1713221.001]
  • [Cites] Sci China B. 1991 Nov;34(11):1312-8 [1666289.001]
  • [Cites] Gynecol Obstet Invest. 1994;37(2):135-40 [8150370.001]
  • [Cites] Nutr Rev. 1994 Feb;52(2 Pt 2):S13-23 [8202278.001]
  • [Cites] Annu Rev Nutr. 1994;14:495-533 [7946531.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11 Suppl):135-9 [8608044.001]
  • [Cites] Neurosci Lett. 1997 Dec 5;238(3):123-6 [9464635.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):26-30 [9705825.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Gen Comp Endocrinol. 2000 Sep;119(3):241-55 [11017772.001]
  • (PMID = 16225703.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Prealbumin; 9007-41-4 / C-Reactive Protein; EC 1.11.1.- / Peroxidases
  • [Other-IDs] NLM/ PMC1274304
  •  go-up   go-down


57. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the hypothesis that ABCs are lesions reactive to local hemodynamics has been challenged after the discovery of specific recurrent chromosomal abnormalities.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


58. Di Mauro D, D'Hoore A, Penninckx F, De Wever I, Vergote I, Hierner R: V-Y Bilateral gluteus maximus myocutaneous advancement flap in the reconstruction of large perineal defects after resection of pelvic malignancies. Colorectal Dis; 2009 Jun;11(5):508-12
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Twelve consecutive patients (seven females and five males), of mean age 59 years (36-78), with primary or recurrent pelvic malignancies (rectal, anal and vulvar carcinoma), underwent either abdomino-perineal rectum excision with partial sacrectomy or total pelvic exenteration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637929.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL: Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol; 2010 Sep;177(3):1087-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amplification of the Notch3 locus has been detected in ovarian high-grade serous carcinoma (HGSC), the most common and malignant type of ovarian cancer.
  • In this study, we provide new evidence that Notch3 expression is associated with recurrent postchemotherapy HGSCs.
  • Moreover, patients with recurrent HGSCs in effusion with high Notch3 expression had a significantly worse clinical outcome, including reduced overall survival and shortened progression-free survival than did patients with low Notch3 expressing HGSC.
  • Ectopic expression of the Notch3 intracellular domain led to an increase in IC(50) for carboplatin in an ovarian surface epithelial cell line and in a low-grade serous carcinoma cell line that expressed undetectable levels of Notch3.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2009 May 7;28(18):1941-8 [19305429.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] PLoS One. 2010;5(6):e11198 [20585448.001]
  • [Cites] Anal Cell Pathol. 2001;23(3-4):107-28 [12082292.001]
  • [Cites] Cell. 2003 May 30;113(5):631-42 [12787504.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4144-9 [12874019.001]
  • [Cites] Cancer. 2004 May 15;100(10):2139-47 [15139056.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] J Reprod Med. 1994 Apr;39(4):241-8 [8040839.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):287-95 [15661210.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1994-2000 [15753399.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):487-91 [16186803.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6312-8 [16778208.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):814-9 [16844205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44 [17130457.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):228-38 [17167759.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):31-44 [17275076.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):749-57 [17429392.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6842-9 [17982121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6326-31 [18436640.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8852-60 [18974129.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1407-15 [19190325.001]
  • [Cites] Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614 [19484149.001]
  • (PMID = 20671266.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA148826; United States / NCI NIH HHS / CA / R01-CA129080; United States / NCI NIH HHS / CA / R01-CA103937; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH3 protein, human; 0 / Receptor, Notch3; 0 / Receptors, Notch; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2928943
  •  go-up   go-down


60. Chessin DB, Hartley J, Cohen AM, Mazumdar M, Cordeiro P, Disa J, Mehrara B, Minsky BD, Paty P, Weiser M, Wong WD, Guillem JG: Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol; 2005 Feb;12(2):104-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite an increased number of anal squamous tumors, an increased vaginectomy rate, increased use of intraoperative radiotherapy, and an increased proportion of cases with recurrent disease, the flap group had a significantly lower rate of perineal wound complications relative to the control group.
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / surgery. Cohort Studies. Combined Modality Therapy / adverse effects. Female. Humans. Male. Middle Aged. Perineum. Radiotherapy, Adjuvant / adverse effects. Rectus Abdominis / surgery. Surgical Flaps. Treatment Outcome


61. Mureşan M, Bancu S, Bara T, Bancu L, Turcu M, Mureşan S: [Local recurrence after the sphincter-saving operations and abdominal perineal resection in rectal cancer]. Chirurgia (Bucur); 2009 Jul-Aug;104(4):415-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recurrent rectal cancer is more frequent in aged patients with high aggressive adenocarcinomas.
  • [MeSH-major] Abdomen / surgery. Adenocarcinoma / surgery. Anal Canal. Neoplasm Recurrence, Local / surgery. Perineum / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / surgery. Aged. Carcinoma, Squamous Cell / surgery. Digestive System Surgical Procedures / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886048.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


62. Andres AH, Walk CB, Meywirth E, Milkereit E: [Awareness under remifentanil-propofol anaesthesia]. Anaesthesist; 2005 Oct;54(10):1000-4
Hazardous Substances Data Bank. PROPOFOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a 49-year-old female patient suffering from recurrent carcinoma of the rectum, who underwent a palliative Hartmann operation for an anus praeter reconstruction.
  • [MeSH-minor] Adenocarcinoma / surgery. Anal Canal / surgery. Female. Hemodynamics / physiology. Humans. Middle Aged. Pain, Postoperative / psychology. Reconstructive Surgical Procedures. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Anaesthesiol Scand. 1997 Sep;41(8):978-84 [9311394.001]
  • [Cites] Curr Opin Anaesthesiol. 2000 Apr;13(2):161-5 [17016296.001]
  • [Cites] Anesth Analg. 1999 Aug;89(2):529-30 [10439780.001]
  • [Cites] Anesthesiology. 1992 Jul;77(1):207-9 [1609996.001]
  • [Cites] Anaesthesist. 2004 Jun;53(6):581-92; quiz 593-4 [15241526.001]
  • [Cites] Anesthesiology. 2000 Feb;92(2):597-602 [10691248.001]
  • [Cites] Anaesthesia. 1998 Mar;53(3):308 [9613280.001]
  • [Cites] Anaesthesia. 1999 Aug;54(8):745-52 [10460526.001]
  • [Cites] Br J Anaesth. 1993 Dec;71(6):782-7 [8280538.001]
  • [Cites] Anaesthesia. 1990 Feb;45(2):153-5 [2321720.001]
  • [Cites] Lancet. 2004 May 29;363(9423):1757-63 [15172773.001]
  • [Cites] Masui. 2001 Aug;50(8):886-9 [11554023.001]
  • [Cites] Trends Neurosci. 1998 Jul;21(7):294-9 [9683321.001]
  • [Cites] Anasthesiol Intensivmed Notfallmed Schmerzther. 2003 Feb;38(2):75-84 [12557119.001]
  • [Cites] Anaesthesia. 1998 Apr;53 Suppl 1:61-7 [9640119.001]
  • [Cites] Anesthesiology. 2001 Feb;94(2):322-32 [11176098.001]
  • [Cites] Lancet. 2000 Feb 26;355(9205):707-11 [10703802.001]
  • (PMID = 15999266.001).
  • [ISSN] 0003-2417
  • [Journal-full-title] Der Anaesthesist
  • [ISO-abbreviation] Anaesthesist
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Piperidines; P10582JYYK / remifentanil; YI7VU623SF / Propofol
  •  go-up   go-down


63. Hatoum OA, Binion DG, Phillips SA, O'Loughlin C, Komorowski RA, Gutterman DD, Otterson MF: Radiation induced small bowel "web" formation is associated with acquired microvascular dysfunction. Gut; 2005 Dec;54(12):1797-800
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These webs are likely to play a role in the pathogenesis of recurrent bowel obstruction.
  • METHODS: A 40 year old patient treated with radiation, two years previously, for an anal squamous cell cancer presented with recurrent small bowel obstruction.
  • [MeSH-minor] Adult. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Microcirculation / physiopathology. Microcirculation / radiation effects

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1986 Apr;10(2):155-70 [3705602.001]
  • [Cites] Cancer. 1975 Jun;35(6):1633-40 [1148997.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):516-26 [3384981.001]
  • [Cites] Pathol Annu. 1988;23 Pt 1:297-330 [3387138.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):865-9 [1914719.001]
  • [Cites] N Engl J Med. 1992 Sep 10;327(11):749-54 [1501650.001]
  • [Cites] Gastroenterology. 1993 Jun;104(6):1832-47 [8500743.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 [7713784.001]
  • [Cites] Circ Res. 1998 Sep 7;83(5):501-7 [9734472.001]
  • [Cites] Free Radic Biol Med. 1998 Nov 1;25(7):826-31 [9823548.001]
  • [Cites] AMA Arch Intern Med. 1955 Jul;96(1):26-31 [14387317.001]
  • [Cites] Trends Cardiovasc Med. 2003 Jul;13(5):201-6 [12837583.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):58-69 [12851871.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1185-9 [12714439.001]
  • [Cites] Surgery. 2004 Oct;136(4):854-60 [15467672.001]
  • [Cites] World J Surg. 1986 Apr;10(2):171-88 [3518250.001]
  • (PMID = 16127018.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774807
  •  go-up   go-down


64. Hoeffel C, Arrivé L, Mourra N, Azizi L, Lewin M, Tubiana JM: Anatomic and pathologic findings at external phased-array pelvic MR imaging after surgery for anorectal disease. Radiographics; 2006 Sep-Oct;26(5):1391-407
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pelvic magnetic resonance (MR) imaging is useful for identification of postoperative changes, complications, and disease recurrence in patients who have undergone surgery for primary or recurrent anorectal disease.
  • Commonly used interventions include treatment for anorectal carcinoma: anterior rectal resection with or without creation of different colic anastomoses and abdominoperineal excision with or without pelvic reconstruction (omentoplasty, placement of myocutaneous flaps).
  • [MeSH-major] Anal Canal / pathology. Anal Canal / surgery. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery. Rectum / pathology. Rectum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2006.
  • (PMID = 16973771.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


65. Tajiri M, Kameda Y, Nakayama H, Sakamoto K: Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area. J Clin Pathol; 2006 Mar;59(3):269-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: It has become obvious that the prognosis of bronchioloalveolar cell carcinoma (BAC) in small peripheral adenocarcinoma of the lung is good, but most cases actually treated as pulmonary adenocarcinoma in hospitals tend to be non-bronchioloalveolar cell carcinoma (non-BAC).
  • RESULTS: The NAAR and HAAR were significantly higher in the recurrent cases than in the recurrence free cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7950-4 [11691817.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]
  • [Cites] Anal Quant Cytol. 1982 Sep;4(3):225-32 [7149488.001]
  • [Cites] Mod Pathol. 1990 May;3(3):314-20 [2362938.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):904-12 [2403196.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):553-62 [8619420.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • (PMID = 16505277.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860342
  •  go-up   go-down


66. Revuz J: Hidradenitis suppurativa. J Eur Acad Dermatol Venereol; 2009 Sep;23(9):985-98
MedlinePlus Health Information. consumer health - Hidradenitis Suppurativa.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hidradenitis suppurativa is a chronic disease characterized by recurrent, painful, deep-seated, rounded nodules and abscesses of apocrine gland-bearing skin.
  • Axillary and inguinal involvement is more common in females; peri-anal and buttocks localizations are prevalent in males.
  • The main complications are arthropathy, carcinoma.

  • Genetic Alliance. consumer health - Hidradenitis Suppurativa.
  • Genetics Home Reference. consumer health - hidradenitis suppurativa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682181.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Steroids; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


67. Tonus C, Neupert G, Glaser HJ, Stienecker K: [Double balloon enteroscopy. First surgical experience]. Chirurg; 2008 May;79(5):474-80
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The approach was oral in 75 cases and anal in 31.
  • Most indications were recurrent middle gastrointestinal bleeding.
  • RESULTS: Complete small intestine inspection could be performed completely orally in seven of 106 examinations; and in most cases a combined oral/anal approach was required.
  • Surgical interventions were indicated in six of 75 patients (8.0%), specifically five small intestinal resections and one bypass operation due to an infiltrating pancreas carcinoma.

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):527-35 [17222315.001]
  • [Cites] Endoscopy. 2005 Jun;37(6):591-3 [15933937.001]
  • [Cites] Endoscopy. 2003 Dec;35(12):985-91 [14648408.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):82-5 [16429360.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):227-30 [11293754.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):545-50 [16185969.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):42-8 [16429354.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1067-73 [15578296.001]
  • [Cites] Gastrointest Endosc. 1986 Dec;32(6):381-4 [3492404.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):62-70 [15990821.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):49-58 [16429355.001]
  • [Cites] Adv Surg. 1989;22:141-77 [2645744.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1010-6 [15551254.001]
  • [Cites] Endoscopy. 2001 Aug;33(8):658-61 [11490380.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):392-8 [16111958.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):59-66 [16429356.001]
  • [Cites] Br J Surg. 1991 Feb;78(2):192-5 [2015470.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):52-7 [16405533.001]
  • [Cites] Endoscopy. 2006 Jan;38(1):67-72 [16429357.001]
  • [Cites] Endoscopy. 2002 Sep;34(9):685-9 [12195324.001]
  • (PMID = 18209985.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G: A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res; 2010;29:132
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA sequencing was able to detect a small number of lower frequency recurrent mutations across the exons screened that were not interrogated using the specific ARMS assays in these studies.
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / genetics. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Lung Neoplasms / genetics. Melanoma / genetics. Skin Neoplasms / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 [2785681.001]
  • [Cites] Hum Mutat. 2004 Apr;23(4):368-78 [15024731.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):207-12 [9056213.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1267-74 [9579832.001]
  • [Cites] Clin Chem. 1998 May;44(5):918-23 [9590362.001]
  • [Cites] Nucleic Acids Res. 1999 Aug 15;27(16):e12 [10454649.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):413-21 [16049314.001]
  • [Cites] Clin Chem. 2006 Apr;52(4):557-8 [16595822.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):642-8 [16827805.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Chest. 2007 Jun;131(6):1628-34 [17565015.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):778-84 [17848912.001]
  • [Cites] Clin Chem. 2008 Apr;54(4):757-60 [18375489.001]
  • [Cites] Cancer Sci. 2008 May;99(5):929-35 [18325048.001]
  • [Cites] Nat Med. 2008 May;14(5):579-84 [18408729.001]
  • [Cites] Eur Respir J. 2009 Jun;33(6):1485-97 [19483050.001]
  • [Cites] Br J Cancer. 2009 Nov 17;101(10):1724-30 [19861964.001]
  • [Cites] Nat Rev Drug Discov. 2010 May;9(5):363-6 [20431568.001]
  • [Cites] Mol Med. 2002 May;8(5):227-37 [12359953.001]
  • [Cites] Pathol Res Pract. 1993 Feb;189(1):66-72 [8390645.001]
  • (PMID = 20925915.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2988723
  •  go-up   go-down


69. Gazdar AF, Gao B, Minna JD: Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer; 2010 Jun;68(3):309-18
Cellosaurus - a cell line knowledge resource. culture/stock collections - HBEC3-KT (CVCL_X491) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perhaps the most important finding is that every important, recurrent genetic and epigenetic change including gene mutations, deletions, amplifications, translocations and methylation-induced gene silencing found in tumors has been identified in cell lines and vice versa.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Oncogene. 2009 Aug;28 Suppl 1:S24-31 [19680293.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):1018-20 [19692681.001]
  • [Cites] PLoS One. 2009;4(10):e7464 [19826477.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1537-47 [10793065.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3200-5 [11306509.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):315-9 [12001993.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4577-86 [12085236.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):65-9 [12170765.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8510-4 [12466971.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2840-5 [15087401.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3060-71 [15126342.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):57-9 [15325095.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7047-52 [15258565.001]
  • [Cites] Cancer Res. 1980 Oct;40(10):3502-7 [6108156.001]
  • [Cites] Science. 1982 Jan 8;215(4529):181-2 [6274023.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Science. 1988 Jul 15;241(4863):353-7 [2838909.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Mar;25(3):527-34 [2539297.001]
  • [Cites] Eur Respir J. 1989 May;2(5):461-9 [2547647.001]
  • [Cites] Science. 1989 Oct 27;246(4929):491-4 [2554494.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):985-91 [8094998.001]
  • [Cites] Exp Cell Res. 1994 May;212(1):36-41 [8174640.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3375-8 [7936665.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5267-74 [17545606.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6007-11 [17616654.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):665-8 [17635116.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2652-63 [17913856.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6555-60 [18006754.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):493-4 [18068625.001]
  • [Cites] Cell Biol Toxicol. 2007 Nov;23(6):367-72 [17522957.001]
  • [Cites] Mol Cancer. 2007;6:75 [18034892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 [18308936.001]
  • [Cites] Anal Biochem. 2008 Apr 15;375(2):237-48 [18211814.001]
  • [Cites] Hum Mutat. 2008 May;29(5):617-22 [18386774.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1053-9 [18304967.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:1-11 [8806089.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:24-31 [8806091.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:152-9 [8806097.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):308-19 [9559342.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):766-74 [9833771.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):2931-8 [9865903.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):991-1000 [10353731.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):725-31 [15677631.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1553-60 [15785753.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2446-8 [15944431.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):1-9 [16157194.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9601-8 [17018617.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e486 [17194187.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):85-102 [17311535.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):815-9 [17429401.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):155-8 [16397413.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2116-28 [16489012.001]
  • [Cites] Differentiation. 2006 Apr;74(4):141-8 [16683984.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1927-35 [16705311.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7870-9 [16912160.001]
  • [Cites] J Cell Mol Med. 2006 Jul-Sep;10(3):588-612 [16989723.001]
  • [Cites] Oncogene. 2008 Jul 31;27(33):4615-24 [18391978.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):810-8 [18523997.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4788-97 [18408757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14112-7 [18776048.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4226-7 [18987282.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3556-65 [19001438.001]
  • [Cites] Clin Transl Oncol. 2008 Nov;10(11):719-25 [19015068.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Jan;296(1):L82-91 [18978040.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):791-800 [19037103.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1795(2):92-103 [19167460.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):508-15 [19234440.001]
  • [Cites] Carcinogenesis. 2009 Apr;30(4):547-54 [19176640.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):489-500 [19477428.001]
  • [Cites] Cell. 2009 May 29;137(5):835-48 [19490893.001]
  • [Cites] Cancer Sci. 2009 Jun;100(6):1040-6 [19385971.001]
  • [Cites] PLoS One. 2009;4(7):e6146 [19582160.001]
  • (PMID = 20079948.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907-14; United States / NCI NIH HHS / CA / P50 CA070907-100003; United States / NCI NIH HHS / CA / CA070907-109001; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / U01CA084971; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-109001; United States / NCI NIH HHS / CA / CA070907-100003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 95
  • [Other-IDs] NLM/ NIHMS295304; NLM/ PMC3110769
  •  go-up   go-down






Advertisement